Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Complement Inhibitors for Macular Degeneration

Award Number: R44EY019191
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/01/2008
PERIOD OF PERFORMANCE END DATE: 07/31/2015

Group Awards By:

View Award Description

Complement Inhibitors for Macular Degeneration - DESCRIPTION (provided by applicant): According to the World Health Organization (WHO) global eye disease survey, 14 million people are blind or severely visually impaired due to age-related macular degeneration AMD. This disease affects the central vision of adults over the age 65. Degenerative changes of the Bruch's membrane and the retinal pigment epithelium in the macula (central retina) in addition to the partial / complete vision loss is the hallmark of AMD. It is estimated that greater than 25% of AMD patients will develop severe vision loss due to either geographic atrophy or Choroidal NeoVascularization (CNV), commonly known as wet AMD. CNV development derives from both inflammation and angiogenesis. Thus, both VEGF and inflammatory mediators must be controlled to prevent CNV associated vision loss. Elevated levels of VEGF have been found in pathological neovascularization. The process of angiogenesis is multi-factorial and highly complex with evidence of both neovascularization and inflammation. VEGF is considered important in both physiological and pathological situations. By blocking all VEGF, local wound healing could be impaired, whereas for any ocular surgery treatment the procedure may then be postponed or even stopped altogether. Both neovascularization and inflammation must be controlled in order to achieve the desired benefit in Wet AMD. A strategy to prevent the formation of VEGF & inflammatory mediators, as opposed to just blocking each of them individually, could be important in halting the progression of the disease. To implement this strategy, NovelMed has developed a high affinity highly selective neutralizing antibody of the alternative pathway that prevents complement and cellular activation and production of inflammatory mediators. In a rabbit model of choroidal neovascularization (CNV), the drug prevented the formation of CNV lesions at a concentration of 15 ug per eye over a 28 day period. We would like to develop The Specific Aims of the project are: 1) Production and Purification of Humanized NM9405 for Aims 2 and 3; 2) Evaluation of Humanized NM9405 in the Rabbit Model of Choroidal NeoVascularization (CNV) and 3) Efficacy & Safety of the Humanized NM9405 in the Cynomolgus Monkey Model of Choroidal Neovascularization (CNV)- - These studies will address ocular efficacy and toxicity studies required for moving to the next step of Investigational New Drug (IND) filings, pharma-partnering, and investment. The demonstration of efficacy and preliminary ocular safety will move this program to an IND stage application.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2014 ( Subtotal = $264,000 )
2014	2014	NOVELMED THERAPEUTICS INC	11000 Cedar Ave Ste 135	Cleveland	OH	44106	CUYAHOGA	USA	Vision Research	001	3	8/26/2014	SUPPLEMENT FOR EXPANSION	$25,000
2014	2014	NOVELMED THERAPEUTICS INC	11000 Cedar Ave Ste 135	Cleveland	OH	44106	CUYAHOGA	USA	Vision Research	000	3	3/28/2014	SUPPLEMENT FOR EXPANSION	$239,000
														Subtotal = $264,000

Issue Date FY: 2013 ( Subtotal = $597,897 )
2013	2013	NOVELMED THERAPEUTICS INC	11000 Cedar Ave Ste 135	Cleveland	OH	44106	CUYAHOGA	USA	Vision Research	000	3	7/11/2013	NON-COMPETING CONTINUATION	$597,897
														Subtotal = $597,897

Issue Date FY: 2012 ( Subtotal = $466,354 )
2012	2012	NOVELMED THERAPEUTICS INC	11000 Cedar Ave Ste 135	Cleveland	OH	44106	CUYAHOGA	USA	Vision Research	000	2	7/16/2012	COMPETING CONTINUATION	$466,354
														Subtotal = $466,354

Grand Total All Awards = $1,328,251

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Complement Inhibitors for Macular Degeneration

Award Number: R44EY019191

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/01/2008

PERIOD OF PERFORMANCE END DATE: 07/31/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer